BUDAPEST Richter acquired a constructive opinion from European regulators recommending that its generic osteoporosis drug Terrosa be granted advertising and marketing authorization, the Hungarian drug maker stated in a press release on Monday.
Richter stated the drug was its first biosimilar product, based mostly on Eli Lily's Forsteo.
Terrosa will probably be bought upon regulatory approval after the advice of the Committee for Medicinal Merchandise for Human Use (CHMP) of the European Medicines Company (EMA).
"The constructive CHMP opinion for our first biosimilar teriparatide marks an vital milestone for our biosimilars enterprise," Richter CEO Erik Bogsch stated within the assertion.
(Reporting by Marton Dunai; modifying by Jason Neely)
No comments:
Post a Comment